Biogen has started a phase 3 trial that it hopes will extend the label for its Skyclarys therapy for inherited neurological disease Friedreich's ataxia (FA) to include children as young as two.

Home ownership remains an aspiration for millions of people, although changing demographic trends and economic pressures mean that today’s first-time buyers have different domestic arrangements ...